Back to today’s briefing

Story perspectives

Treeline Biosciences Launches Phase 1 Trials for Cancer Drugs

9/6/2025

41 6 Full Breakdown

Summary

Story summary

Treeline Biosciences has initiated Phase 1 trials for three cancer drugs and raised $200 million in funding.
Co-founders Josh Bilenker and Jeff Engelman emphasize targeted cancer therapies.
This is Treeline's first public announcement of its clinical candidates.
NuCana utilizes ProTide technology to enhance cancer treatment, with NUC-7738 and NUC-3373 in trials.
Both companies aim to improve outcomes for cancer patients.

1 of 1

Story summary

Treeline Biosciences has initiated Phase 1 trials for three cancer drugs and raised $200 million in funding.
Co-founders Josh Bilenker and Jeff Engelman emphasize targeted cancer therapies.
This is Treeline's first public announcement of its clinical candidates.
NuCana utilizes ProTide technology to enhance cancer treatment, with NUC-7738 and NUC-3373 in trials.
Both companies aim to improve outcomes for cancer patients.